Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 18 of 28.
Jan 2015
30 Jan · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Third Quarter ended December 31, 2014.
Dec 2014
31 Dec · Disclosure of Voting Pattern - Clause 35A
29 Dec · News Verification
News Verification : The media had reports that "Glenmark to out-license molecule". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Glenmark Pharmaceuticals Limited has vide its letter inter-alia stated, "As a part of its business, the Company enters into discussions with various Pharmaceutical Companies (Interested licensees) with respect to its innovative product pipeline. Such discussions are mostly exploratory and may or may not result in a business deal. We confirm that at present there are no negotiations taking place."29 Dec · Legal
Exchange has sought clarification from Glenmark Pharmaceuticals Limited with reference to recent news item captioned "Glenmark to out-licence molecule". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The reply from the Company is Awaited.16 Dec · Court Convened Meeting Updates
Nov 2014
28 Nov · Meeting
21 Nov · Disclosure of Voting Pattern - Clause 35A
Oct 2014
22 Oct · Meeting
22 Oct · Court Convened Meeting Updates
17 Oct · Board meeting
To consider and approve the Company's Unaudited Financial Statements for the Second Quarter/Half year ended September 30, 2014. Further, as per the "Code of Conduct for Prevention of Insider Trading" of the Company, the trading window shall remain closed for Directors and other designated employees of the Company from October 17, 2014 to October 31, 2014 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter/Half year ended September 30, 2014.
Sep 2014
Aug 2014
Jul 2014
28 Jul · Disclosure of Voting Pattern - Clause 35A
25 Jul · Meeting
At the Annual General Meeting held on July 25, 2014 the shareholders have approved following: Dividend of Rs. 2 per share of Re. 1 each (200%) on the Equity Share Capital of the Company for the financial year ended 2013-2014.24 Jul · Board meeting
Board of Directors of the Company at its Meeting held on July 24, 2014 allotted 24,100 equity shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Jun 2014
May 2014
8 May · Dividend
Board of Directors of the Company at its meeting held on May 08, 2014, inter alia, has recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2013-2014 subject to the approval of the Shareholders at the ensuing Annual General Meeting.
Apr 2014
22 Apr · Updates
Glenmark loses its appeal to invalidate Abbott Laboratories TARKA (trandolapril/verapamil hydrochloride) patent when the Court of Appeals for the Federal Circuit, USA affirmed the district court's decision today regarding Glenmark's marketing of a generic equivalent of TARKA. Glenmark is disappointed with the decision and is considering its options.